@article{cdb0e0bd7d0f409999f1fe7e555311d6,
title = "Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus",
abstract = "Introduction Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues. Methods A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1=disagree and 9=agree). Results First-line antipsychotics varied depending on predominant symptoms: risperidone (mean±standard deviation score, 7.9±1.4), olanzapine (7.5±1.6), and aripiprazole (6.9±1.9) were more likely selected for positive symptoms; aripiprazole (7.6±1.6) for negative symptoms; aripiprazole (7.3±1.9), olanzapine (7.2±1.9), and quetiapine (6.9±1.9) for depression and anxiety; and olanzapine (7.9±1.5) and risperidone (7.5±1.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6±1.0) in patients without noticeable symptoms, aripiprazole (8.0±1.6) and brexpiprazole (6.9±2.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5±2.0) and aripiprazole (6.9±2.1). Discussion These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature.",
keywords = "antipsychotics, expert consensus, pharmacotherapy, schizophrenia",
author = "Hitoshi Sakurai and Norio Yasui-Furukori and Takefumi Suzuki and Hiroyuki Uchida and Hajime Baba and Koichiro Watanabe and Ken Inada and Kikuchi, {Yuka Sugawara} and Toshiaki Kikuchi and Asuka Katsuki and Ikuko Kishida and Masaki Kato",
note = "Funding Information: Dr. Sakurai reports grants from the Japanese Society of Clinical Neu-ropsychopharmacology and the Uehara Memorial Foundation, and personal fees from Dainippon-Sumitomo Pharma, Otsuka Pharmaceutical, Meiji-Seika Pharma, Eli Lilly, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin, outside the submitted work. Dr. Norio Yasui-Furukori has been a speaker for Dainippon-Sumitomo Pharmaceutical, Mochida Pharmaceutical, Otsuka Pharmaceutical, and MSD for other studies within the past 3 years. The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. Dr. Suzuki has received manuscript or speaker{\textquoteright}s fees from Astellas, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Meiji Seika Pharma, Mitsubi-shi Tanabe Pharma, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Shire, Tsumura, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, Meiji Seika Pharma, and Shionogi. Dr. Uchida has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, and Meiji-Seika Pharmaceutical; speaker{\textquoteright}s honoraria from Otsuka Pharmaceutical, Eli Lilly, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, and MSD; and advisory panel payments from Dainippon-Sumitomo Pharma with- Publisher Copyright: {\textcopyright} 2021 American Institute of Physics Inc.. All rights reserved.",
year = "2021",
month = mar,
day = "1",
doi = "10.1055/a-1324-3517",
language = "English",
volume = "54",
pages = "60--67",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "2",
}
